INNV-03. INSTITUTION SPECIFIC CLINICAL TRIAL MATCHING WEB APPLICATION FOR CENTRAL NERVOUS SYSTEM METASTASES

Abstract

Abstract BACKGROUND Current clinical trials evaluating treatment options for patients with brain metastases are tailored to a number of clinical factors, including type of underlying cancer, number of brain metastases, size and volume of brain metastasis, prior treatment, and genomic characterization. A multidisciplinary brain metastasis tumor board was established at our institution in January 2023. Subsequently, an institution specific clinical trial matching web application was developed in-house to screen and match subjects for trials accruing at our institution. METHODS We reviewed our institution’s list of phase III surgical, radiation, and medical oncology clinical trials specific for brain metastasis to identify the most discriminating inclusion criteria that can be used as a basis for branching and differentiation. These disease specific trials were then individually assessed according to these criteria and these results were populated in a common separated value (CSV) file. RESULTS A web application was created using Python for analysis of the CSV and incorporating branching logic. HTML, CSS, and JavaScript were used for building the webpage interface. The web application is hosted on our institutional server and can be utilized to search available clinical trials for each patient being presented during tumor board. CONCLUSION We developed an institution specific web application that can be used to screen patients for various clinical trials. By developing this application and hosting it internally, we are able to edit the components at our discretion. The methodology for this web-build can be applied to other disease sites or institutions. This web application is useful for screening our institution’s clinical trial portfolio to identify potential gaps, and can also be used to avoid competing trials. This web application significantly reduces the time to identify protocol eligibility and has increased clinical trial enrollment.